This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Esnaola, N. F. Articles by Kuntz, K. M. Search for Related Content PubMed PubMed Citation Articles by Esnaola, N. F. Articles by Kuntz, K. M. Social Bookmarking                            What's this?

Outcomes and Cost-Effectiveness of Alternative Staging Strategies for Non–Small-Cell Lung Cancer

From the Department of Surgery, Brigham and Women’s Hospital, CHASE Management Systems, Partners HealthCare, Inc, and the Department of Health Policy and Management, Harvard School of Public Health, Boston, MA.

Address reprint requests to Nestor F. Esnaola, MD, MPH, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Box 444, Houston, TX 77030-4009; email: nesnaola{at}mdanderson.org

PURPOSE: To identify the optimal strategy for staging the mediastinum of patients with known non–small-cell lung cancer (NSCLC), stratified by tumor (T) classification.

METHODS: We used a decision-analytic model to compare the health outcomes and cost-effectiveness of three staging strategies: (1) chest computed tomography alone, (2) selective mediastinoscopy, and (3) routine mediastinoscopy. The overall effectiveness and cost of each strategy was a function of the proportion of patients accurately staged and the risks, benefits, and costs of the diagnostic tests and treatments used. Probability estimates and costs were derived from primary data and the literature. We adopted a societal perspective and calculated incremental cost-effectiveness ratios (ICERs) as cost per quality-adjusted life year (QALY) gained.

RESULTS: Both mediastinoscopy strategies correctly identified more patients with mediastinal involvement (N2/N3 disease) and assigned them to multimodal regimens. Routine mediastinoscopy maximized quality-adjusted life expectancy in all patients, irrespective of T classification, and this result was robust to varying the model estimates over their reported ranges. In T1 patients, selective mediastinoscopy cost $24,500 per QALY gained, compared with $78,800 per QALY gained for routine mediastinoscopy. In T2 and T3 patients, the ICER of routine mediastinoscopy was more favorable ($42,800 and $53,400 per QALY gained, respectively).

CONCLUSION: Routine mediastinoscopy maximizes quality-adjusted life expectancy in patients with known NSCLC, and its ICER compares favorably with other currently accepted medical technologies. The survival benefit and cost-effectiveness of this strategy are greater in patients with T2 and T3 tumors and are likely to improve with advances in multimodal therapy.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				C. Gessner, C. Woischwill, A. Schumacher, U. Liebers, H. Kuhn, P. Stiehl, K. Jurchott, H.D. Royer, C. Witt, and G. Wolff Nuclear YB-1 expression as a negative prognostic marker in nonsmall cell lung cancer Eur. Respir. J., January 1, 2004; 23(1): 14 - 19. [Abstract] [Full Text] [PDF]

				A. Toker, Y. Bayrak, S. Tanju, S. Ziyade, O. Eroglu, D. Yilmazbayhan, S. Dilege, and G. Kalayci Invasive staging of superior mediastinum in non-small cell lung cancer patients with specific indications Interactive CardioVascular and Thoracic Surgery, December 1, 2003; 2(4): 472 - 476. [Abstract] [Full Text] [PDF]